Home » Stocks » TYME

Tyme Technologies, Inc. (TYME)

Stock Price: $1.80 USD 0.00 (0.00%)
Updated Mar 8, 2021 2:35 PM EST - Market open
Market Cap 306.77M
Revenue (ttm) n/a
Net Income (ttm) -27.52M
Shares Out 130.17M
EPS (ttm) -0.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 8
Last Price $1.80
Previous Close $1.80
Change ($) 0.00
Change (%) 0.00%
Day's Open 1.81
Day's Range 1.73 - 1.88
Day's Volume 2,322,381
52-Week Range 0.85 - 4.99

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
The Motley Fool - 3 weeks ago

The company closed a $100 million public stock offering.

Business Wire - 1 month ago

BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that tod...

The Motley Fool - 1 month ago

The clinical-stage biotech provides investors with a quarterly update.

Business Wire - 1 month ago

BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced financia...

Benzinga - 1 month ago

Business Wire - 1 month ago

BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTsTM), today announced t...

The Motley Fool - 1 month ago

The U.S. Patent and Trademark Office is on Tyme's side.

Benzinga - 1 month ago

Tyme Technologies Inc (NASDAQ: TYME) shares are nearly doubling on above-average volume Wednesday. Tyme, which focuses on developing cancer metabolism-based therapies, said the U.S. Patent and...

Business Wire - 1 month ago

BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that it ...

Seeking Alpha - 2 months ago

Revisiting Tyme Technologies

Business Wire - 2 months ago

BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that an ...

Business Wire - 3 months ago

BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTsTM), announced that, e...

Insider Monkey - 3 months ago

In this article we are going to use hedge fund sentiment as a tool and determine whether Tyme Technologies, Inc. (NASDAQ:TYME) is a good investment right now. We like to analyze hedge fund sen...

Business Wire - 3 months ago

BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced financia...

Business Wire - 4 months ago

BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that its...

Seeking Alpha - 5 months ago

TYME Technologies: My Bamboo Speculation In A Potential Leader In Cancer Metabolism-Based Therapies.

Seeking Alpha - 5 months ago

Tyme has a solid product candidate in pancreatic cancer.

Business Wire - 5 months ago

BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc.

Business Wire - 5 months ago

NEW YORK--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ:TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that its leadersh...

Business Wire - 5 months ago

NEW YORK--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that its leaders...

Business Wire - 6 months ago

NEW YORK--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that its leaders...

Business Wire - 6 months ago

BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc.

Business Wire - 6 months ago

BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc.

Business Wire - 6 months ago

BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc.

Benzinga - 7 months ago

Tyme Technologies (NASDAQ: TYME) shares are trading higher on Monday after the company announced an orphan drug designation for its SM-88 as a potential treatment for patients with pancreatic ...

Business Wire - 7 months ago

BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc.

Business Wire - 7 months ago

NEW YORK--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that its leaders...

Benzinga - 7 months ago

Tyme Technologies Inc (NASDAQ:TYME) was trading 1.7% lower from the previous closing price.

Business Wire - 7 months ago

NEW YORK--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced preliminary fina...

Business Wire - 7 months ago

NEW YORK--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that TYME will h...

Benzinga - 8 months ago

Tyme Technologies Inc (NASDAQ:TYME) was trading 0.2% lower from the previous closing price.

Business Wire - 8 months ago

NEW YORK--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced new preclinical ...

Business Wire - 8 months ago

NEW YORK--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced new preclinical ...

Seeking Alpha - 9 months ago

Tyme Technologies, Inc. (TYME) CEO Steve Hoffman on Q4 2020 Results - Earnings Call Transcript

Seeking Alpha - 11 months ago

Tyme Technologies: Market Volatility Provides Opportunity To Accumulate Ahead Of Catalysts

Seeking Alpha - 1 year ago

Circling Back On Tyme Technologies

GlobeNewsWire - 1 year ago

NEW YORK, Jan. 16, 2020 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced t...

Seeking Alpha - 1 year ago

Tyme Technologies: Why Investors Should Be Bullish On The Eagle Partnership

Zacks Investment Research - 1 year ago

Tyme (TYME) is evaluating its lead cancer candidate, SM-88, as third-line treatment for metastatic pancreatic cancer in a pivotal study.

Zacks Investment Research - 1 year ago

Tyme's (TYME) shares rise as the company inks deal with Eagle Pharmaceuticals to co-promote its investigational cancer metabolism-based therapy, oral SM-88, in the United States.

Market Watch - 1 year ago

Shares of Tyme Technologies were up 23% in premarket trading on Tuesday after the biotechnology company said it had formed a collaboration with Eagle Pharmaceuticals Inc.

GuruFocus - 1 year ago

Falling knives are companies whose share prices have declined more than 59% over the last 52 weeks.

Other stocks mentioned: MOGU
GlobeNewsWire - 1 year ago

NEW YORK, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that ma...

Seeking Alpha - 1 year ago

Tyme Technologies, Inc. (TYME) CEO Steve Hoffman on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

NEW YORK, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism based therapies (CMBTs™), announced that i...

Seeking Alpha - 1 year ago

Tyme Technologies has several pending events that could inject some positive momentum into the stock. One of these is the final Phase II data for the TYME-88-PANC study at ESMO.

GlobeNewsWire - 1 year ago

NEW YORK, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that m...

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor Tyme Technologies.

GlobeNewsWire - 1 year ago

NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that m...

Seeking Alpha - 1 year ago

Tyme Technologies utilizes its Cancer Metabolism-Based Therapies ((CMBTs)) to treat cancers with a huge unmet medical need.

About TYME

Tyme Technologies, a clinical-stage biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma. The company also offers TYME-18, a CMBT compound that is in preclinical stage for the treatment of solid tumors. Tyme Technologies, Inc. has a research collaboration with NYU Langone Health to advance the development of treatments f... [Read more...]

Industry
Biotechnology
Founded
2011
Stock Exchange
NASDAQ
Ticker Symbol
TYME
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for TYME stock is "Buy." The 12-month stock price forecast is 8.75, which is an increase of 386.11% from the latest price.

Price Target
$8.75
(386.11% upside)
Analyst Consensus: Buy